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Tissue engineering of large bone defects is approached through
implantation of autologous osteogenic cells, generally referred to
as multipotent stromal cells or mesenchymal stem cells (MSCs).
Animal-derived MSCs successfully bridge large bone defects, but
models for ectopic bone formation as well as recent clinical trials
demonstrate that bone formation by human MSCs (hMSCs) is
inadequate. The expansion phase presents an attractive window
to direct hMSCs by pharmacological manipulation, even though no
profound effect on bone formation in vivo has been described so
far using this approach.We report that activation of protein kinase
A elicits an immediate response through induction of genes such as
ID2 and FosB, followed by sustained secretion of bone-related
cytokines such as BMP-2, IGF-1, and IL-11. As a consequence, PKA
activation results in robust in vivo bone formation by hMSCs
derived from orthopedic patients.
bone tissue engineering  osteogenesis  PKA signaling
The ability of human mesenchymal stem cells (hMSCs) to differen-tiate into adipogenic, chondrogenic, osteogenic (1), and myogenic
(2) lineages has generated a great deal of potential clinical use in
regenerative medicine and tissue engineering in the past decade.
Concomitantly, hMSCs are increasingly used as a cell biological model
system to investigatemolecularmechanisms governing signal transduc-
tion (3), differentiation (4–6), cell fate decision (7), and senescence (8,
9) because the step from basic research to clinical application is
relatively short. Although hMSCs are multipotent and form mineral-
ized bone tissue in vivo, their clinical application is still limited. Using a
bone tissue engineering approach, large bone defects can be repaired
in animal models by using animal-derived MSCs. For instance, Petite
et al. (10) demonstrated bone union in a metatarsal defect in sheep. In
contrast, bone formation by hMSCs is substantially less robust, and
repair of critical size bone defects has not been achieved by hMSCs so
far (11).
Predifferentiation of hMSCs into the osteogenic lineage in vitro
during the expansion phase before implantation offers an opportunity
to improve their in vivo performance. In previous studies, dexameth-
asone (dex) and vitamin D3 were used to promote hMSC differenti-
ation in vitro (12).Morerecent studies include theMAPKpathway(13),
Rho kinase (7),Wnt (5), Notch (14), and receptor tyrosine kinases (3).
So far, no positive correlation between hMSC osteogenesis in vitro and
bone formation in vivo has been reported. Although many reports
describe the positive effect of compounds onosteogenesis in vitro, there
are, to the best of our knowledge, no convincing reports where in vitro
manipulation of clinically applicable hMSCs significantly augments
bone formation in vivo. Either no in vivo experiments were performed
or the effect on bone formation is marginal and sometimes even
negative (15, 16). In other studies, transgenic immortalized hMSC
derivative was used (3, 9).
Protein kinase A (PKA) signaling plays a prominent but ambig-
uous role in mesenchymal cell fate decision, which depends on the
molecular and developmental context in which the PKA signal is
presented (17, 18). Relatively little is known about the role of PKA
in osteogenic differentiation of hMSCs, but it is anticipated by the
anabolic effect of certain PKA-activating hormones on bone min-
eral density. Intermittent administration of parathyroid hormone
increases trabecular and cancelleous bone formation in ovariecto-
mizedmice, although continuous administration results in net bone
loss (19). The effect of PKA activation on osteogenesis has been
studied in different cell types with compounds that directly or
indirectly activate PKA, although the results are contentious. The
most direct evidence on a role of PKA in osteogenic differentiation
is from studies in calcifying vascular cells (20).Here activation of the
PKA pathway with N6,2-O-dibutyryladenosine-3,5-cyclic mono-
phosphate (db-cAMP) stimulated the expression of osteogenic
marker genes and in vitro mineralization, suggesting that the PKA
pathway promotes vascular calcification by enhancing osteogenic
differentiation of calcifying vascular cells. Furthermore, the PKA
activator forskolin increased bone nodule formation at low con-
centrations but inhibited it at higher concentrations (21). A recent
study shows that parathyroid hormone-related peptide (PTHrP)
inhibits CBFA1 expression through the PKA pathway (22), and it
has been reported that PKA activation enhances adipogenic dif-
ferentiation of hMSCs (18). In this article we describe that PKA-
activated hMSCs demonstrate enhanced in vitro osteogenesis and in
vivo bone formation, which opens a promising window of oppor-
tunity to further improve bone tissue engineering protocols.
Results
cAMP/PKA Signaling Induces Osteogenesis in hMSCs. To assess the
effect of PKA activation on osteogenesis in hMSCs, we exposed a
panel of hMSCs, isolated from the bone marrow of 14 patients
undergoing orthopedic surgery ranging 31–82 years of age [sup-
porting information (SI) Table S1], to the PKA activator db-cAMP.
Both dex and db-cAMP consistently enhanced the expression of the
early osteogenic marker alkaline phosphatase (ALP), ranging from
a 1.8-fold increase to a 5.3-fold increase compared with untreated
controls (see Fig. 1a and Fig. S1a). Donor variation was observed
both in the basal level of ALP expression, as reported by us
previously (23), and in their response to both agents (Fig. S1a).
db-cAMP-inducedALP expression did not depend on the presence
of dex, although coexposure resulted in an additive and sometimes
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synergistic effect on ALP expression, resulting in up to 60% of
ALP-positive cells in some donors. Consistent with a positive effect
on ALP expression, calcium deposition was enhanced when db-
cAMP was administered to hMSCs in mineralization medium (Fig.
1b). Optimal stimulation of mineralization was observed when
hMSCs were exposed to db-cAMP during the first 5 days of
osteogenic culture, resulting in a 3-fold increase in mineralization
compared with treatment with dex alone. Incubation for 15 days
resulted in a significant inhibition of mineralization. The positive
effect of PKA signaling on osteogenesis was further confirmed by
quantitative PCR (qPCR) on a panel of osteogenic marker genes
during a 15-day osteogenic time course. db-cAMP had a significant
positive effect onALP andCOL1A1 expression fromday 3 until day
15 (Fig. S2). Dex and db-cAMP together induced the expression of
the transcription factor CBFA1 on days 5 and 15. In contrast, OPN
expression was induced only at day 10 by dex or dex and db-cAMP
and appears to be a dex-mediated event. BGLAP,ON, and S100A4
showed no consistent difference in expression profile during the
course of osteogenic differentiation.
To demonstrate that db-cAMP mediates its effect through
activation of PKA, we exposed cells to two other upstream PKA
activators, cholera toxin and forskolin, and confirmed that also
these compounds stimulate ALP expression in hMSCs (Fig. 1c and
Fig. S1b).When hMSCswere exposed to db-cAMPor cholera toxin
in the presence of H89, an inhibitor of PKA activity, PKA-induced
ALP was reduced to basal level. Interestingly, H89 did not signif-
icantly affect dex-induced ALP expression, showing that dex and
db-cAMP stimulate ALP expression through discrete molecular
mechanisms (Fig. 1c). One of the direct target proteins of PKA is
cAMP response element-binding protein (CREB), and indeed we
detected phosphorylated CREB in hMSCs upon treatment with
db-cAMP (Fig. 1d). Evidently, treatment of hMSCs with db-cAMP
leads to PKA activation, which stimulates in vitro osteogenic
differentiation of hMSCs.
cAMP/PKA Signaling Enhances in Vivo Bone Formation by hMSCs. To
evaluate the effect of db-cAMP on in vivo bone formation we used
the ectopic bone formationmodel in immune-deficient mice, which
is widely used to assess the bone-forming capacity of hMSCs (3, 9,
11, 24). Using this model, we typically observe a bone/ceramic
surface ratio of 15–20% for goat MSCs, as shown in Fig. 2a. This
represents 50% of the available pore area, and all of the pores
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Fig. 1. PKA activation induces in vitroosteogenesis of hMSCs. (a) Box plot showing the average percentage of ALP-positive cells from 14 donors in basic medium
(Con), osteogenic medium (Dex), basic medium with 1 mM db-cAMP (cAMP), or osteogenic medium supplemented with 1 mM db-cAMP (DexcAMP). The data
were analyzed by using two-way ANOVA followed by Dunnet’s multiple-comparison test. Statistical significance is denoted compared with the control group.
(b) hMSCs were grown in either mineralization medium (dex) or mineralization medium to which 1 mM db-cAMP was added during the first 3, 5, 10, 15, 25, or
full 30 days after which calcium deposition was measured and expressed as micrograms of calcium per milliliter of sample. The data were analyzed by using
one-way ANOVA followed by Dunnet’s multiple-comparison test. (c) H89, a PKA inhibitor, reverses the db-cAMP-induced ALP expression. hMSCs were
preincubated with H89 for 10–15 h and then cotreated with db-cAMP or cholera toxin (CTX) for 4 days. The data were analyzed by using one-way ANOVA
followed by Tukey’s multiple-comparison test. (d) Addition of db-cAMP to hMSCs for 6 h resulted in increased phosphorylation of transcription factor CREB, which
could be inhibited by coincubation with H89. *, P  0.05; **, P  0.01.
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contain bone tissue. In contrast, 1–2% bone/ceramic surface ratio
is observed when hMSCs were grown in the presence or absence of
dex (Fig. 2a). To assess whether db-cAMP-treated hMSCs display
enhanced bone formation, we analyzed ectopic bone formation by
hMSCs from 11 donors undergoing orthopedic surgery. First,
hMSCs from three donors were seeded onto porous calcium
phosphate ceramics and cultured for 7–10 days in basic medium.
During the last 4 days, the cells were grown in the presence or
absence of 1 mM db-cAMP. In vivo bone formation by hMSCs
increased from 1.5% in the control group up to 6% upon db-cAMP
exposure (Fig. 2b). To further investigate the potential application
of db-cAMP-treated hMSCs in bone tissue engineering, we tested
the effect of db-cAMP in two alternative strategies currently under
investigation: peroperative seeding of hMSCs and bioreactor-
mediated bone tissue engineering.We expanded hMSCs from eight
donors and changed the medium to basic medium or basic medium
containing 1mMdb-cAMP 4 days before implantation. On the day
of the operation, we trypsinized the cells, allowed them to attach to
porous ceramic scaffolds for 4 h, and analyzed bone formation using
ectopic implantation model. Surprisingly, we observed no bone
formation in the control group except for one donor (Fig. 2 c and
d). Apparently, peroperative seeding represents a so far unreported
very stringent tissue engineering protocol. In contrast, bone for-
mation was observed in seven of eight donors analyzed (Fig. 2 c and
d) whereas the bone/ceramic surface ratio increased up to 8% (Fig.
2c) upon exposure to db-cAMP. When the data from Fig. 2 b and
c are combined the average bone/scaffold surface ratio significantly
increases from 1.0  1.2% by untreated cells to 5.6  2.7% when
db-cAMP-treated hMSCs were implanted (P 0.01 using one-way
ANOVA).
Next we investigated whether db-cAMP could be implemented
in bioreactor-mediated bone tissue engineering. Methylene blue
staining of tissue-engineered constructs grown for 7 days in a
bioreactor suggested that db-cAMP had a negative effect on cell
proliferation (Fig. S3a). We confirmed this with hMSCs grown in
2D, where db-cAMP dose-dependently inhibited hMSC prolifera-
tion (Fig. S3b). Moreover, db-cAMP-treated hMSCs displayed a
17-fold up-regulation ofGAS1 (see Table S2), a gene that is known
Fig. 2. db-cAMP augments the in vivo bone-forming capacity of hMSCs. (a) hMSCs were cultured on BCP particles in basic medium (Con) or osteogenic medium
(Dex) for 7 days and implanted s.c. in nude mice for 6 weeks. Histomorphometric analysis demonstrates that osteogenic medium does not affect in vivo bone
formation. Note the amount of bone formed by an equal number of goat-derived MSCs (G-MSCs) in an independent experiment. (b) In vivo bone formation by
hMSCs from three donors using the standard tissue engineering approach (see Materials and Methods). ns, not significant. (c) Bone formation using the
peroperative seeding approach. Note the consistent increase in bone formation upon db-cAMP treatment. The data from b and c were analyzed by using
Student’s t test compared with their respective controls. (d) Incidence of bone formation using the peroperative seeding approach by hMSCs from five donors.
(e) In vivo bone formation by hMSCs cultured in a perfusion bioreactor system in proliferation medium (con) or proliferation medium supplemented with 1 mM
db-cAMP (cAMP). The data were analyzed by using Student’s t test. ( f) A representative histological section showing newly formed bone (red), matrix-embedded
osteocytes (white arrow), and lining osteoblasts (black arrow). (g) Bone marrow-like tissue was seen at multiple places in bone derived from db-cAMP-treated
hMSCs (white arrow). *, P  0.05.
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to inhibit cell proliferation (25). Despite the negative on prolifer-
ation, db-cAMP-treated hMSCs produced three times more bone
(15% bone/ceramic surface ratio) than untreated control cells
(5%), which is equal to the amount of bone deposited by goatMSCs
(Fig. 2a). Histological examination of the explanted grafts showed
that mature bone was formed in which osteocytes were embedded
in mineralizing extracellular matrix (Fig. 2f) and mineralizing
osteoblasts could be detected. Polarizing light microscopy of the
deposited matrix showed areas of lamellar bone, which indicates
that bone tissue has been remodeled by osteoclasts and osteoblasts
(Fig. S4).Moreover, marrow-like tissue was observed in the vicinity
of the tissue-engineered bone, which further indicates the function-
ality of the bone tissue (Fig. 2g) (24).
Autocrine and Paracrine Induction of Bone Formation by cAMP/PKA-
Activated hMSCs. Based on the robust effect of db-cAMP on bone
formation in vivo, which is in striking contrast to the effect of dex,
we anticipated that PKA activation results in the expression of a
unique set of target genes ultimately resulting in osteogenic differ-
entiation in vitro and bone formation in vivo. To get more insight
into the molecular mechanism behind db-cAMP-induced bone
formation, we compared the gene expression profile of untreated
cells with that of hMSCs treated with db-cAMP for 6 h using DNA
microarray technology. Among the 62 genes up-regulated six times
or more by db-cAMP (Table S2), a number of genes were previ-
ously associated with cAMP/PKA signaling. Six genes were iden-
tified in chip-on-chip assays for CREB-binding promoters (CREM,
RCC1, GP-1, FLRT3, GPRC5A, and EVX-1; see http://natural.
salk.edu/CREB/) whereas other genes have been implicated in
cAMP/PKA signaling, e.g., ID-2 (26), BMP-2 (27), IGF-1 (28), and
IL-11 (29). To show that the genes are directly activated by PKA
signaling, we demonstrated that db-cAMP-mediated ID-2 expres-
sion is insensitive to cyclohexamide, an inhibitor of translation (Fig.
3a). Gene Ontology enrichment of the data set further showed a
remarkably high number of transcription factors (nine of the top 62
up-regulated genes). Three transcription factors are implicated in
osteogenesis [c-Fos, FosB, and ID-2 (30)], but others were previ-
ously not implicated in osteogenesis, such as BCL3, EVX1, CDX2,
DUX1,DAT1, and ID-4.Wedid not observe the classical osteogenic
transcription factors such as CBFA1 (31) and OSX/SP7 (32) in our
microarray data set. We also analyzed the gene expression profile
of hMSCs at the time of implantation. Gene Ontology enrichment
of genes up-regulated five times or more in hMSCs treated for 7
days with db-cAMP shows that, at this point in time, hMSCs express
many secreted proteins, mostly growth factors and cytokines (Table
S3). Most striking is the 46-fold up-regulation of BMP-2, which
suggests that autocrine or paracrineBMPsignaling is involved in the
osteogenic effect of db-cAMP. To investigate this, we analyzed the
expression of ID-1, a typical BMP target gene, by qPCR during
db-cAMP-driven in vitro differentiation. When hMSCs were ex-
posed to db-cAMPanddex, ID-1 expressionwas significantly higher
on day 5 compared with db-cAMP alone. Dex alone did not affect
ID-1 expression compared with untreated cells (Fig. 3b). Other
cytokines that have been implicated in osteogenesis and bone
formation (IGF-1, IL-8, and IL-11) (33) ranked among the most
highly regulated genes (19-, 47-, and 18-fold up-regulated, respec-
tively; see Table S3).We confirmed the secretion of these cytokines
by db-cAMP-treated hMSCs usingELISA (Fig. 3c). In this case, the
induction is even more drastic. Another interesting set of cytokines
up-regulated in the 7-day treatment group are proteins interfering
with vasculogenesis such as angiopoietin-like 2, angiopoietin-like 4,
and placental growth factor. Based on the putative involvement of
BMP and other secreted proteins, we propose a model for db-
cAMP-induced bone formation in which paracrine signaling
through hMSC-secreted cytokines and growth factors stimulates
bone formation in vivo (Fig. 4).
Discussion
The osteogenic potential of hMSCs has been long recognized and
provides the exciting potential to treat patients with bone defects
beyond spontaneous healing (1, 34). Successful bone formation has
been reported for animal models, but so far bone formation by
hMSCs is limited and recent clinical trials have demonstrated that
in vivo bone formed by the implanted hMSCs is insufficient (11).
Bone tissue engineering may be augmented through systemic
administration of osteogenic agents or by scaffold-mediated deliv-
ery of biologically active reagents (35). Manipulation of hMSCs
during in vitro expansion is an interesting alternative because, in this
approach, the agents used in vitro can be cleared from the graft
before implantation with minimal regulatory and safety implica-
tions.As such, large libraries of smallmolecules can be screened and
used for their desired biological effect (36). The lack of irrefutable
data demonstrating that predifferentiation of hMSCs in vitro results
in enhanced bone formation in vivo led us to investigate whether
db-cAMP treatment enhances in vivo performance of hMSCs. Our
data describe the osteogenic effect of PKA activation in hMSCs,
and we demonstrate that in vitro manipulation of hMSCs with the
small molecule db-cAMP results in robust osteogenic differentia-
tion in vitro and bone formation in vivo. The mechanism of action
seems to be different from that used by dex and may involve
paracrine/autocrine signaling by BMPs and other osteogenic cyto-
kines. However, other mechanisms such as improved survival of
db-cAMP-treated cells or enhanced angiogenesis cannot be ex-
Fig. 3. db-cAMP-induced gene and protein expression. (a) hMSCs were
treated with cycloheximide for 1 h and then coincubated with db-cAMP for 6
more hours. Expression of BMP target genes ID-1 and ID-2 was analyzed
compared to cycloheximide-treated cells. The data were analyzed by using
Student’s t test. (b) hMSCs were grown in basic medium, basic medium
supplemented with 1 mM db-cAMP (cAMP), osteogenic medium (Dex), or
osteogenic medium supplemented with 1 mM db-cAMP (DexcAMP). Expres-
sion of ID-1was analyzed by qPCR and is expressed as fold induction compared
with cells grown in basic medium. The data were analyzed by using two-way
ANOVA. Statistical differences are denoted compared with cells grown in
basic medium. (candd) db-cAMP induces secretion of proosteogenic cytokines
and growth factors. hMSCs were treated with db-cAMP for 4 days, the super-
natant was collected, and IGF-1 (c), IL-8, and IL-11 (d) expression in the medium
was measured by ELISA. The data were analyzed by using Student’s t test. **,
P  0.01.
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cluded, which warrants further research to confirm our model
(Fig. 4).
We evaluated the potential application of db-cAMP-treated
hMSCs in bone tissue engineering by testing its effect on in vivo
bone formation using different tissue engineering strategies cur-
rently in use: standard tissue engineering, peroperative seeding, and
bioreactor-based bone tissue engineering. In the peroperative seed-
ing strategy, hMSCs are poli-clinically isolated from a bonemarrow
biopsy or alternative sources such as fat tissue (37) and expanded.
On the day of the surgery, cells are seeded onto the scaffold
material and implanted in the defect (38). In addition, automated
bioreactor systemsmay play a role in future bone tissue engineering
because a clinical research team can harvest a biopsy and expand
and differentiate cell-seeded grafts in routine clinical laboratories
up to the time of implantation. Prototypes of bioreactors have been
reported by us and others (39, 40). In our hands, bioreactor-
mediated bone tissue engineering is the most efficient method. We
are trying to enhance bone formation even further by improving the
proliferation phase of MSCs before db-cAMP treatment and by
finding themost optimal balance between induction of osteogenesis
and cell proliferation. With further improvement on the prolifer-
ation and differentiation scheme, we hope to consistently achieve a
15–20% bone/ceramic surface ratio.
The data presented in this article describe for the first time that
bone formation by hMSCs can be significantly augmented through
manipulation of the signal transduction milieu in vitro by using a
simple compound like db-cAMP. This work once again demon-
strates the enormous plasticity of hMSCs and strongly encourages
further efforts to engineer the gene expression profile of hMSCs for
optimal clinical application.
Materials and Methods
Isolation, Culture, and ALP Analysis of hMSCs. Bone marrow aspirates were
obtained from donors with written informed consent, and hMSCs were isolated
and proliferated as described previously (41). Briefly, aspirates were resuspended
by using 20-gauge needles, plated at a density of 5  105 cells per square
centimeter and cultured in hMSC proliferation medium containing -MEM (Life
Technologies), 10% FBS (Cambrex), 0.2 mM ascorbic acid (Asap; Life Technolo-
gies), 2 mM L-glutamine (Life Technologies), 100 units/ml penicillin (Life Technol-
ogies), 10 g/ml streptomycin (Life Technologies), and 1 ng/ml basic FGF (In-
struchemie). Cells were grown at 37°C in a humid atmosphere with 5% CO2.
Medium was refreshed twice a week, and cells were used for further subculturing
or cryopreservation. hMSC basic medium/control medium was composed of
hMSC proliferative medium without basic FGF, hMSC osteogenic medium was
composed of hMSC basic medium supplemented with 108 M dex (Sigma), and
hMSC mineralization medium was composed of basic medium supplemented
with 108 M dex and 0.01 M -glycerophosphate (Sigma). Donor information is
provided in Table S1.
Osteogenic Assay. To determine whether PKA activation elicits an osteogenic
response in hMSCs, we exposed them to 1 mM db-cAMP (Sigma) with or without
dex for 4 days and analyzed the expression of the osteogenic marker ALP by flow
cytometry. hMSCs were seeded at 5,000 cells per square centimeter and allowed
to attach for 10–15 h in basic medium, then cells were incubated with 108 M dex
and 1 mM db-cAMP for the denoted time periods. Each experiment was per-
formed in triplicate with a negative control (cells grown in basic medium) and a
positive control (cells grown in the presence of dex) and one or more experimen-
tal conditions. At the end of the culture period, the cells were trypsinized and
incubated for 30 min in block buffer [PBS with 5% BSA (Sigma) and 0.05% NaN2],
then incubated with primary antibody (anti-ALP, B4-78; Developmental Studies
Hybridoma Bank, University of Iowa) diluted in wash buffer (PBS with 1% BSA
and 0.05% NaN2) for 30 min or with isotype control antibodies. Cells were then
washed three times with wash buffer and incubated with secondary antibody
(rabbitanti-mouse IgGphycoerythrin;DAKO)for30min.Cellswerewashedthree
times and suspended in 250 l of wash buffer with 10 l of Viaprobe (Pharmin-
gen) for live/dead cell staining, and only live cells were used for further analysis.
The percentage of ALP-positive cells was calculated on a FACSCalibur (Becton
Dickinson Immunocytometry Systems). Mineralization was measured quantita-
tively by using a calcium assay kit (Sigma Diagnostics; 587A) according to the
manufacturer’sprotocolafterculturingthecells forthedenotedtimeperiodwith
the compounds mentioned.
Gene Expression Analysis by qPCR and Microarray. The effect of db-cAMP on
expression of osteogenic marker genes was analyzed by seeding hMSCs at 5,000
cells per square centimeter in T75 flasks supplemented in various medium com-
positions for 3, 5, 10, and 15 days. To analyze the direct induction of BMP target
genes by PKA activation, hMSCs were seeded at 5,000 cells per square centimeter
and supplemented with 1 mM db-cAMP for 6 h with or without 10M cyclohex-
imide (Sigma). RNA was isolated by using an RNeasy mini kit (Qiagen), and qPCR
was performed by using SYBR green (Invitrogen) on a Light Cycler (Roche). Data
were analyzed by using Light Cycler software version 3.5.3, using the fit point
method by setting the noise band to the exponential phase of the reaction to
exclude background fluorescence. Expression of osteogenic marker genes was
calculated relative to 18s rRNA levels by the comparative 	CT method (42). To
study the genome-wide effect of db-cAMP, hMSCs were grown in either basic
medium or basic medium supplemented with 1 mM db-cAMP for 6 h or 7 days.
RNA was isolated by using an RNeasy midi kit (Qiagen), and 8g of total RNA was
used for probe labeling according to the manufacturer’s protocol (Affymetrix).
The probe quality was verified by using lab-on-chip technology (Agilent Tech-
nologies), and samples were hybridized to Human Genome Focus arrays accord-
ing to the manufacturer’s protocol (Affymetrix). Data analysis was performed by
using Affymetrix GENECHIP 4.0 software. CREB (Calbiochem), phosphorylated
CREB (R & D Systems), and-actin (R & D Systems) antibodies were used to detect
respective proteins by Western blotting on cell lysates obtained from hMSCs
treated with various supplements. IGF-1, IL-8, and IL-11 secretion upon db-cAMP
treatment was measured in the cell supernatant by ELISA (R & D Systems) accord-
ing to the manufacturer’s protocol.
In Vivo Evaluation Studies. To evaluate the effect of PKA activation on ectopic
bone formation by hMSCs, we used three tissue engineering protocols.
Standard tissue engineering approach. As scaffold for all bone tissue engineering
methods, we used porous biphasic calcium phosphate (BCP) ceramic granules of
2–3 mm, prepared and sintered at 1,150°C as described previously (43). The cells
were cultured for 7 days in basic medium, in osteogenic medium, or in osteogenic
medium supplemented with 1 mM db-cAMP during the last 4 days. Goat MSCs
were isolated and expanded as described previously (40).
Peroperative seeding approach. To investigate the performance of db-cAMP-
treated hMSCs in the peroperative seeding approach, we expanded hMSCs from
eight donors and changed the medium to basic medium or medium containing
1 mM db-cAMP 4 days before implantation. On the day of the operation, we
Fig. 4. Model for autocrine/paracrine induction of osteogenesis in hMSCs by
PKA signaling. db-cAMP induces direct expression of BMP target genes such as
ID-2 and ID-4 via CREB resulting in cell-autonomous stimulation of osteogen-
esis whereas expression of BMP-2, proosteogenic cytokines, and growth fac-
tors results in paracrine induction of bone formation.
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trypsinized the cells and allowed them to attach to porous BCP scaffolds for 4 h
as described above.
Bioreactor-based tissue engineering. hMSCs were seeded onto porous ceramics as
described above, transferred into a bioreactor, and cultured for 4 days in basic
medium.Adirectperfusionflowbioreactorwasusedasdescribedpreviously (40).
Briefly, the bioreactor comprised an inner and outer housing, which are config-
ured as coaxially disposed, nested cylinders. The bioreactor system consisted of a
bioreactor, a sterile fluid pathway (made of -sterilized PVC tubing with low gas
permeability) that includes a medium supply vessel, a pump, an oxygenator, and
a waste vessel. The fluid pathway contained a temperature sensor and two
dissolved oxygen sensors, which are placed at the medium inlet and outlet of the
bioreactor. The whole bioreactor system was placed in a temperature-controlled
unit at 37°C. The incubation units were equipped with controlled oxygen and
carbon dioxide supplying systems. The gas environment in the chamber is kept at
a constant level of 21% O2 and 5% CO2, and medium is pumped through the
gas-permeable tube. This system enables a medium flow over and through the
cell-seeded biomaterials with constant pH and a constant oxygen concentration.
During the last 4 days, the cells in the bioreactor were or were not supplemented
with 1 mM db-cAMP perfused through the medium.
At the end of the culture period, the tissue-engineered constructs were
implanted s.c. in immune-deficient mice for 6 weeks. In each in vivo experiment,
10 nude male mice (Hsd-cpb:NMRI-nu; Harlan) were anesthetized by intramus-
cular injection of 0.05 ml of anesthetic (1.75 ml of 100 g/ml ketamine, 1.5 ml of
20mg/mlxylazine,and0.5mlof0.5mg/mlatropine).Fours.c.pocketsweremade,
and each pocket was implanted with three particles of each condition. The
incisionswereclosedwithavicryl5-0 suture,andthetissue-engineeredconstructs
were left for 6 weeks. All experiments were approved by the local Animal
Experimental Committee.
Histology and Histomorphometry. After 6 weeks, the mice were killed by using
CO2 and samples were explanted, fixed in 1.5% glutaraldehyde (Merck) in 0.14 M
cacodylic acid (Fluka) buffer (pH 7.3), dehydrated, and embedded in methyl
methacrylate (Sigma) for sectioning. Approximately 10-m-thick, undecalcified
sections were processed on a histological diamond saw (Leica saw microtome
cutting system). The sections were stained with basic fuchsin and methylene blue
to visualize new bone formation. The newly formed mineralized bone stains red
with basic fuchsin, all other cellular tissues stain light blue with methylene blue,
and the ceramic material remains black and unstained by both the dyes. Histo-
logical sections were qualitatively analyzed by using a light microscope (Leica),
and each histological section was scored either positive or negative for bone
formation. Quantitative histomorphometry was performed as described previ-
ously (44). Briefly, high-resolution digital photographs (300 dpi) were made from
four randomly selected sections from each tissue-engineered graft. Before his-
tomorphometrical analysis, bone and material were pseudocolored green and
red, respectively, by using Photoshop CS2 (Adobe Systems). Image analysis was
performed by using a PC-based system with KS400 software (version 3, Zeiss). A
custom-made macro was used to measure bone/ceramic surface ratios.
Cell distribution on the scaffold and matrix formation were qualitatively
visualized with methylene blue staining. The tissue-engineered constructs were
immersed in 1% methylene blue solution for 1 min and washed three times with
demineralized water to remove unbound stain. The BCP particles remain un-
stained while cells stain blue when examined by light microscopy. To assess the
effect of db-cAMP on proliferation, cells were seeded in basic medium at 5,000
cellspersquarecentimetereitherwithorwithout1mMdb-cAMPfor5days.Next,
themediumwasremovedand2mlofa10%Alamarblue(Biosource)solutionwas
added and incubated for 4 h. From this, 0.2 ml was transferred to a 96-well plate
and measured on a spectrophotometer (PerkinElmer) at 545 nm.
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